Segments

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

SEGMENTS

SEGMENTSWe manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended March 31,
(In thousands)	2022		2021
Revenue from services:
Pharmaceutical	$	—	$	—
Diagnostics	286,599		506,951
Corporate	—		—
	$	286,599	$	506,951
Revenue from products:
Pharmaceutical	$	36,658	$	33,945
Diagnostics	—		—
Corporate	—		—
	$	36,658	$	33,945
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	5,962	$	4,269
Diagnostics	—		—
Corporate	—		—
	$	5,962	$	4,269
Operating income (loss):
Pharmaceutical	$	(18,108)	$	(19,157)
Diagnostics	(43,548)		67,014
Corporate	(10,768)		(9,420)
	$	(72,424)	$	38,437
Depreciation and amortization:
Pharmaceutical	$	15,402	$	7,413
Diagnostics	12,412		12,576
Corporate	—		—
	$	27,814	$	19,989
Loss from investment in investees:
Pharmaceutical	$	(49)	$	(43)
Diagnostics	—		—
Corporate	—		—
	$	(49)	$	(43)
Revenues:
United States	$	291,808	$	512,871
Ireland	8,462		7,129
Chile	16,339		14,152
Spain	7,109		5,919
Israel	1,558		2,512
Mexico	3,750		2,418
Other	193		164
	$	329,219	$	545,165

(In thousands)	March 31, 2022		December 31, 2021
Assets:
Pharmaceutical	$	1,099,633	$	1,114,460
Diagnostics	1,152,173		1,238,583
Corporate	55,052		46,672
	$	2,306,858	$	2,399,715
Goodwill:
Pharmaceutical	$	236,028	$	237,576
Diagnostics	283,024		283,025
	$	519,052	$	520,601

No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2022 and 2021. As of March 31, 2022 and December 31, 2021, no customer represented more than 10% of our accounts receivable balance.